The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft ModelsAlwin G. Schuller, Celina M. D’Cruz|Clinical Cancer Research|2015Cited by 80
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancersTeeru Bihani, Celina M. D’Cruz|Oncotarget|2014Cited by 57